NCT04874155已完成不适用
A Multi-Center, Randomized, Double-Blind, Sham-Controlled Study to Evaluate the NTX100 Neuromodulation System for Patients With Medication-Refractory Primary Restless Legs Syndrome (RLS) - The RESTFUL Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 133
- 试验地点
- 14
- 主要终点
- Number of Subjects for Which the Clinician Reported "Much Improved" or "Very Much Improved" on the Clinical Global Impressions-Improvement (CGI-I) Scale for TOMAC Compared to Sham
研究概览
简要总结
Multi-center, prospective double-blind randomized controlled pivotal study of noninvasive peripheral nerve stimulation (NPNS) with the NTX100 Neuromodulation System for patients with medication-refractory moderate-severe primary RLS
详细描述
The study consists of a series of two 4-week phases:
Phase 1: Prospective, double-blinded, 1:1 randomized (Active treatment: Sham control)
Phase 2: Prospective, non-randomized, non-blinded, Active treatment
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
盲法说明
Double-blind
入排标准
- 年龄范围
- 22 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has received a medical diagnosis of primary restless legs syndrome (RLS).
- •Subject is refractory to RLS medication (as defined in section 7.3).
- •Subject has moderate-severe RLS symptoms as defined by a score of 15 or greater points on IRLS (International Restless Legs Syndrome Study Group Rating Scale [12]) over the week prior to study entry.
- •Subject has RLS symptoms 2 or more nights per week during the week prior to study entry as defined by a score of 2, 3, or 4 on IRLS question #
- •RLS symptoms are most significant in the subject's lower legs and/or feet.
- •RLS symptoms are most significant at bedtime, after bedtime, and/or in the 2 hours before bedtime.
- •RLS symptoms between 10am and 6pm are not severe.
- •Subject agrees to not change dosage or schedule of any medications that are known to impact RLS symptoms during the study, including RLS medications, antidepressants, sleep medications, or sedative antihistamines.
- •Subject agrees to not make major lifestyle changes during the study including diet, exercise, career, or other changes that would affect bedtime.
- •Subject possesses the necessary equipment, internet/phone accessibility, and communication ability to complete electronic questionnaires and respond to electronic communications and phone calls from the research staff throughout the in-home portion of the study.
- •Subject is ≥ 22 and ≤ 79 years of age when written informed consent is obtained.
- •Subject has signed a valid, IRB-approved informed consent form, can understand the requirements of the study and instructions for device usage, and can converse in English
排除标准
- •Subject has RLS that is known to be caused by another diagnosed condition (i.e. secondary RLS).
- •Subject is taking an unstable or inconsistent dose or schedule of medication that is likely to impact RLS symptoms, such as antidepressants, sleep medications, or sedative antihistamines or has changed dosage within the past 30 days.
- •Subject has changed dose and schedule of RLS medications within the month prior to study entry or is otherwise on an inconsistent dose or schedule of RLS medications.
- •Subject reports having significant prior experience with neurostimulation devices (including but not limited to TENS devices) or subject has prior experience with neurostimulation devices developed by the study sponsor.
- •Subject was misdiagnosed with RLS, as determined by the investigator (e.g. actual diagnosis of PLMD, arthritis, leg spasms or neuropathy without comorbid RLS).
- •Subject has a sleep disorder other than RLS that interferes with sleep at the present time (except for obstructive sleep apnea that is stably controlled via CPAP).
- •Subject has active medical device implant anywhere in the body (including but not limited to pacemakers, spinal cord stimulators, deep brain stimulators) or metal implant in the leg.
- •Subject has failed a nerve conduction study prescribed by a physician or has been diagnosed with severe peripheral neuropathy.
- •Subject reports that bedtime is typically outside of 9pm-3am or reports that bedtime regularly varies by more than 4 hours, such as due to shift work.
- •On nights with no RLS symptoms (if any), subject reports typical sleep onset latency of >60min.
- •Subject has been diagnosed with one of the following conditions:
- •Epilepsy or other seizure disorder
- •Current, active or acute or chronic infection other than common cold
- •A malignancy within the past 5 years (not including basal or squamous cell skin cancer)
- •Stage 4-5 chronic kidney disease or renal failure
- •Severe movement disorder symptoms (Parkinson's disease, Huntington's disease, dyskinesia, dystonia)
- •Deep vein thrombosis
- •Multiple sclerosis
- •Subject has moderate or severe cognitive disorder or mental illness.
- •Subject has current diagnosis of iron-deficient anemia or history of iron-deficient anemia within the past year.
- •Subject has known allergy to device materials, electrode gel, polyurethane foam, or lycra (or severe previous reaction to medical adhesives or bandages).
- •Subject has severe edema affecting lower legs.
- •Subject has any of the following at or near the location of device application.
- •Acute injury
- •Cellulitis
- •Open sores
- •Other skin condition
- •Subject is on dialysis or anticipated to start dialysis while participating in the study.
- •During the NTX100 calibration process, which is identical for subjects in the active and sham arms, subject reports not feeling stimulation sensations up to an intensity of 30mA or finds stimulation intensities less than 15 mA to be uncomfortable or distracting.
- •Subject has received another investigational device or drug within 30 days before study entry, is planning to receive another investigational device or drug during the study, or is planning to change RLS medications during the study.
- •Subject has undergone a major surgery (excluding dental work) in the 30 days prior to study entry.
- •Subject is unable or unwilling to comply with study requirements.
- •Subject is pregnant or trying to become pregnant.
- •Subject has a medical condition not listed above that may affect validity of the study as determined by the investigator.
- •Subject has a medical condition not listed above that may put the subject at risk as determined by the investigator
结局指标
主要结局
Number of Subjects for Which the Clinician Reported "Much Improved" or "Very Much Improved" on the Clinical Global Impressions-Improvement (CGI-I) Scale for TOMAC Compared to Sham
时间窗: Week 4
Responder rate is defined as the proportion of responses of "Much Improved" or "Very Much Improved" relative to baseline on the investigator-rated 7-point CGI-I scale.
次要结局
- Responder Rate on Patient Global Impressions-Improvement (PGI-I) Scale(Week 4)
- Mean Change From Baseline in International Restless Legs Syndrome Study Group Rating Scale (IRLS) Score(Week 4)
- Mean Change From Baseline in Medical Outcomes Study Sleep Problems Index II (MOS-II) Score(Week 4)
- Mean Change From Baseline in Medical Outcomes Study Sleep Problems Index I (MOS-I) Score(Week 4)
- Mean Clinical Global Impressions-Improvement (CGI-I) Scale Rating(Week 4)
- Score for Question #7 of the International Restless Legs Syndrome Study Group Rating Scale (IRLS)(Week 8)
研究者
研究点 (14)
Loading locations...
相似试验
招募中
2 期
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With DupilumabAtopic DermatitisNCT05694884ASLAN Pharmaceuticals75
终止
2 期
Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)Bladder CancerNCT01475266Nippon Kayaku Co., Ltd.51
已完成
不适用
RCT of Non-Invasive Vagus Nerve Stimulation (nVNS) With gammaCore®, for the Acute Treatment of Migraine AttacksMigraineNCT02686034ElectroCore INC285
已完成
3 期
Efficacy and Safety Evaluation Study of Neuramis® Deep Lidocaine in Correction of Nasolabial FoldNasolabial FoldNCT02751034Medy-Tox60
已完成
不适用
CellFX System for the Treatment of Cutaneous Non-Genital WartsWartsWarts HandVerrucaNCT04554394Pulse Biosciences, Inc.62